Using implementation interventions and peer recovery support to improve opioid treatment outcomes in community supervision: Protocol

Martin, Rosemarie A.; Stein, L. A. R.; Rohsenow, Damaris J.; Belenko, Steven; Hurley, Linda; Clarke, Jennifer G.; Brinkley‐Rubinstein, Lauren

doi:10.1016/j.jsat.2021.108364

Cited by 13 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those in the experimental arm will meet with a PSS for 12 months, and PSSs can help establish linkages to treatment, provide education, share skills, and set goals. The outcome of interest includes engagement in MOUD ( 43 ). Lastly, a research team will test an adapted version of the evidence-based Recovery Management Checkups (RMC), which provides MOUD linkage, support for retention, and re-linkage at quarterly checkups with a Linkage Manager.…”

Section: Resultsmentioning

confidence: 99%

Access to medications for opioid use disorder for formerly incarcerated individuals during community reentry: a mini narrative review

Chladek,

Chui

2024

Front. Public Health

View full text Add to dashboard Cite

Medications for opioid use disorder (MOUD) are especially important for formerly incarcerated individuals with opioid use disorder (OUD) and can reduce the risk of re-arrest and overdose during community reentry. Unfortunately, few formerly incarcerated individuals are able to access MOUD within the community, missing a critical tool for rehabilitation. A mini narrative review was conducted to highlight the published work that has been done to improve access to MOUD for formerly incarcerated individuals during reentry. The results yielded 15 records describing intervention evaluations, program descriptions, and research in progress. Most work is ongoing, showing promise that researchers have identified the importance of this problem. However additional research should be done to include other stakeholders and address the limitations of existing interventions and programs. Continued efforts can help ensure that formerly incarcerated individuals can safely and successfully reintegrate into society.

show abstract

Section: Resultsmentioning

confidence: 99%

Access to medications for opioid use disorder for formerly incarcerated individuals during community reentry: a mini narrative review

Chladek,

Chui

2024

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…Encouragingly, MOUD stigma can be acted on. A series of recent randomized controlled trials to promote MOUD uptake include components that address MOUD stigma, such as facilitation collaboration with community-based treatment settings ( 40 ), implementation coaches ( 41 ), and local change teams ( 42 ). The findings from our study suggest that there may be opportunities for counselor training interventions that specifically focus and standardize how to present medications to their clients with OUD.…”

Section: Discussionmentioning

confidence: 99%

Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder

Cardamone,

Stewart,

Kampman

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Medications for opioid use disorder (MOUD) are among the best tools we have to combat the opioid epidemic. Yet, use of MOUD among people with opioid use disorder (OUD) remains low. Interventions to increase MOUD access in the United States have largely focused on improving organizational capacity and addressing funding barriers, yet stigma toward MOUD may inhibit uptake even where MOUD is readily available. Substance use disorder (SUD) treatment counselors likely have considerable influence on a client’s choice to initiate and adhere to MOUD, but beliefs that counselors convey about MOUD in interaction with clients are understudied. The current study explores what advantages and disadvantages that SUD treatment counselors communicate about buprenorphine, methadone, and naltrexone. Methods: From June to December 2021, we surveyed counselors from publicly-funded SUD treatment agencies under a municipality-wide mandate to offer MOUD to all clients with OUD. Counselors were asked to describe, in a free-response format, the most important advantages and disadvantages to communicate to their clients about taking buprenorphine, methadone, and naltrexone. Counselor responses were coded for one or more advantage and disadvantage. Results: A total of 271 SUD counselors from 29 agencies completed the survey, generating 1,995 advantages and disadvantages across three types of MOUD. The most frequently reported advantage across all three types of MOUD was their ability to reduce cravings and illicit drug use. The most frequently reported disadvantage related to the potential for some types of MOUD to develop long-term medication dependence. Conclusions: As the availability and variety of MOUD treatment options continue to expand, it is important that SUD counselors are equipped with evidence-based recommendations for OUD care. We identified misalignments with the MOUD-prescribing evidence base and stigmatizing language toward MOUD within counselors’ responses, highlighting the potential to refine training materials for MOUD and mitigate stigmatizing beliefs.

show abstract

“…In a recent trial, patient navigation was associated with a significantly greater percentage of individuals on probation receiving referrals and linkage to primary care compared to control group participants who only received informational booklets (O'Connell et al, 2020). Notably, this pilot by O'Connell et al (2020) concurrently used a system change intervention which used local change teams to more effectively facilitate linkage to primary care through intersectoral collaborations (e.g., community corrections agencies and officers, clients, and healthcare providers), an approach that has been used to connect justice-involved individuals with HIV testing (Belenko et al, 2017) and substance use disorder treatment (Elkington, Lee, Brooks, Watkins, & Wasserman, 2020;Howell et al, 2021;Martin et al, 2021;McCarty et al, 2007). Support for these approaches is encouraging (Belenko et al, 2017), but several of these studies are still ongoing (e.g., Howell et al, 2021;Martin et al, 2021).…”

Section: Discussionmentioning

confidence: 99%

“…Notably, this pilot by O'Connell et al (2020) concurrently used a system change intervention which used local change teams to more effectively facilitate linkage to primary care through intersectoral collaborations (e.g., community corrections agencies and officers, clients, and healthcare providers), an approach that has been used to connect justice-involved individuals with HIV testing (Belenko et al, 2017) and substance use disorder treatment (Elkington, Lee, Brooks, Watkins, & Wasserman, 2020;Howell et al, 2021;Martin et al, 2021;McCarty et al, 2007). Support for these approaches is encouraging (Belenko et al, 2017), but several of these studies are still ongoing (e.g., Howell et al, 2021;Martin et al, 2021). It should also be noted, however, that the syringe exchange that women in this study used also has significant healthcare resources available to participants, yet the difference in preference for healthcare location was still found.…”

Section: Discussionmentioning

confidence: 99%

Healthcare beliefs, health information seeking, and healthcare setting preferences among women who inject drugs by community supervision status

et al. 2021

View full text Add to dashboard Cite

Objective Women on community supervision who inject drugs have significant unmet healthcare needs. However, it remains unclear how the intersection of community supervision and injection drug use influences healthcare experiences and service setting preferences. The present study examines whether the intersection of community supervision and injection drug use is associated with differences in women’s healthcare beliefs, healthcare experiences, and service setting preferences. Methods A secondary analysis was conducted on a previously collected sample of women who inject drugs recruited from a syringe exchange and social service organization for a cross-sectional survey. Participants (N = 64) were mostly White (75%), and more than a quarter were currently on probation or parole (26%). Results Independent samples t-tests and chi-square tests revealed no significant differences on sociodemographic variables by community supervision status. There were no significant differences by community supervision status across seven indicators of healthcare confidence (ps > .05). However, results revealed significant differences in past experiences and beliefs about healthcare, health information seeking, and healthcare setting preferences by community supervision status (ps < .05), where women on community supervision less frequently sought health information and medical care outside of emergency departments. Conclusions Findings provide preliminary evidence about differences in the healthcare experiences and setting preferences of women who inject drugs on community supervision.

show abstract

Using implementation interventions and peer recovery support to improve opioid treatment outcomes in community supervision: Protocol

Cited by 13 publications

References 22 publications

Access to medications for opioid use disorder for formerly incarcerated individuals during community reentry: a mini narrative review

Access to medications for opioid use disorder for formerly incarcerated individuals during community reentry: a mini narrative review

Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder

Healthcare beliefs, health information seeking, and healthcare setting preferences among women who inject drugs by community supervision status

Contact Info

Product

Resources

About